SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

Open Letter to FDA Commissioner: Investigate Gardasil Clinical Trials

By 262 Comments

The following open letter to FDA Commissioner, Dr. Scott Gottlieb, calling for immediate investigations into many facets of the clinical trials for Gardasil sponsored by Merck was emailed today. If you support this request, please leave a note in the comment section below that includes your name, title, and organization. Help the FDA understand how […]

[Continue reading...]

Prophylactic HPV Vaccines: Current Knowledge of Impact on Gynecological Premalignancies

By Leave a Comment

Authors: Diane M. Harper and Karen B. Williams Abstract: Approaches for cervical cancer prevention are changing. Screening still remains the most effective method for cervical cancer prevention. Guidelines are moving to an older group of women to be screened less frequently with combinations of technologies that include biomarkers and cytology. HPV vaccination is an appropriate option for […]

[Continue reading...]

HPV Vaccine Debate in South Africa

By 7 Comments

By Norma Erickson 9 August 2015, a citizen of South Africa (we’ll call her Sarah) sent the following questions about HPV vaccines to CANSA, the Cancer Association of South Africa. Sarah had no idea her questions would lead to a full-blown scientific debate. Could you please let me know why CANSA is supporting the use […]

[Continue reading...]

Reduction in HPV prevalence?

By Leave a Comment

Is 'protecting' against 4 types of HPV enough to warrant the risks?

[SaneVax: Following is an excerpt from a letter to the editor of The Journal of Infectious Diseases that provides a critique of a scientific study used to demonstrate the success of HPV vaccination programs in the United States. Evidently, things are not so cut and dried as the CDC would like us to believe.] Reduction in HPV Prevalence—No […]

[Continue reading...]

What if HPV does NOT cause cervical cancer?

By 42 Comments

Sanevax square

Cervical Cancer? By Norma Erickson and Peter H. Duesberg, PhD The title of a paper recently published by McCormack et al in Molecular Cytogenetics says it all, ”Individual karyotypes at the origins of cervical carcinomas.” If the findings in this paper are true, a vaccine against human papillomavirus (HPV) is extremely unlikely to protect against […]

[Continue reading...]

From Human Papillomavirus (HPV) Detection to Cervical Cancer Prevention in Clinical Practice

By Leave a Comment

Cervical Cancer Prevention Sin Hang Lee, Jessica S. Vigliotti, Veronica S. Vigliotti and William Jones Abstract: The newly gained knowledge of the viral etiology in cervical carcinogenesis has prompted industrial interests in developing virology-based tools for cervical cancer prevention. Due to the long incubation period from viral infection to developing an invasive cancer, a process whose […]

[Continue reading...]

Do HPV vaccines target the right strains for Colombia?

By Leave a Comment

Sanevax square

Right Strains? By Sandy Lunoe, Guest Author There is a most relevant question which should immediately be addressed regarding the HPV vaccine program in Colombia. The question does not in this instance refer to the worrying fact that many girls have fallen seriously ill after commencement of the HPV vaccine program. It concerns specifically whether […]

[Continue reading...]

Common Sense Cervical Cancer Prevention

By Leave a Comment

Cervical Cancer Prevention [SaneVax: If the point of HPV vaccination is to prevent cancer, then the efficacy of HPV vaccines will not be evident for decades. Since HPV infections almost always resolve without disease – why is there such a push for HPV vaccination programs? Read this article to learn a common-sense approach to cervical cancer […]

[Continue reading...]

What if HPV infections are beneficial, not deadly?

By Leave a Comment

Is 'protecting' against 4 types of HPV enough to warrant the risks?

[SaneVax: What would happen if scientists discovered that naturally acquired HPV infections helped reduce the risk of future infections and abnormal cell development?  Would vaccine manufacturers admit they may have made a mistake and go back to the drawing board? Would the FDA be a little more cautious next time they considered fast-tracking a vaccine for […]

[Continue reading...]

Potential cross reactivity between HPV 16 L1 protein and sudden death-associated antigens

By Leave a Comment

Potential cross reactivity Cross Reactivity… J Exp Ther Oncol. 2011;9(2):159-65. Kanduc D. Author information Abstract In exploring the primary sequence of the human papilloma virus (HPV) 16 major capsid L1 protein for peptide sharing with human proteins, we find that 34 pentamers from the viral capsid protein are shared with human proteins that, when altered, have […]

[Continue reading...]

Is human papillomavirus vaccination likely to be a useful strategy in India?

By Leave a Comment

India …Strategy in India  Sudeep Gupta, Rajendra A. Kerkar,1 Rajesh Dikshit,2 and Rajendra A. Badwe1 Author information ► Copyright and License information ►   .. Abstract Two vaccines that protect against infection by some of the oncogenic human papillomavirus (HPV) subtypes have recently been licensed for use in population-based vaccination strategies in many countries. However, these products are being promoted as ‘cervical cancer […]

[Continue reading...]

HPV vaccination not cost effective

By Leave a Comment

HPV vaccination programs have been shown to be not cost effective in countries with comprehensive Pap screening and surgery Abstract By Judy Wilyman Pap screening combined with loop electrosurgical excision procedures (LEEP) is almost 100% effective in preventing cervical cancer mortality yet many countries with these procedures have now implemented broad HPV vaccination programs. HPV […]

[Continue reading...]

INEFFICACY OF THE HPV VACCINE SEEN BY DOCTOR OF DEEP PERÚ

By 1 Comment

From initial infection until the appearance of cervical carcinoma (UCC) takes an average 25 to 30 years.  The research of this vaccine began in the 1990’s. It is evident that the scientific efficacy of this new vaccine will be determined somewhere around the years 2025 – 2040. HPV has not been established as THE cause […]

[Continue reading...]

Gardasil: New Study Brings More Safety Questions to Light

By 18 Comments

  By Norma Erickson, President Why were HPV-16 L1 DNA fragments detected in post mortem samples taken six months after Gardasil vaccination and not the other vaccine-relevant types? Dr. Sin Hang Lee, of Milford Hospital and Milford Molecular Laboratory, may have provided an answer in his most recently published paper entitled, Topological conformational changes of […]

[Continue reading...]

Topological conformational changes of human papillomavirus (HPV) DNA bound to an insoluble aluminum salt—A study by low temperature PCR

By Leave a Comment

Gardasil Cervarix HPV Vaccine Survey

Author(s):  Sin Hang Lee ABSTRACT A low temperature (LoTemp®) polymerase chain reaction (PCR), conducted at cycling temperatures not to exceed 85℃and catalyzed by a novel highly processive HiFi® DNA polymerase with proofreading function, was used to study the topological conformational changes of the human papillomavirus (HPV) L1 gene DNA fragments bound to the insoluble amorphous aluminum […]

[Continue reading...]

Commentary on the Editorial: “HPV Prevention Series” authored by Silvia de Sanjosé

By Leave a Comment

Gardasil Cervarix HPV Vaccine Survey

[SaneVax: In an unprecedented move, medical consumers from multiple countries have come together to protest half-truths and misinformation being used to promote HPV vaccination campaigns. In response to an editorial by Sylvia de Sanjosé published in Infectious Agents and Cancer entitled HPV Prevention series, the following letter was written to the editors of the journal. True to the spirit of BioMed […]

[Continue reading...]

HPV vaccines and cancer prevention, science versus activism

By Leave a Comment

Lucija Tomljenovic, Judy Wilyman, Eva Vanamee, Toni Bark and Christopher A Shaw Infectious Agents and Cancer 2013, 8:6 doi:10.1186/1750-9378-8-6 Published: 1 February 2013 Abstract (provisional) The rationale behind current worldwide human papilloma virus (HPV) vaccination programs starts from two basic premises, 1) that HPV vaccines will prevent cervical cancers and save lives and, 2) have no risk of serious side effects. Therefore, efforts […]

[Continue reading...]

No Human Papillomavirus Type Replacement After HPV Vaccination?

By 1 Comment

Gardasil Cervarix HPV Vaccine Survey

[SaneVax: Science Daily recently published an article on a large scale study that headlined HPV types do not replace those suppressed via vaccination. Unfortunately, if you read the article carefully, it clearly states that all of the data for this ‘study’ came from an unvaccinated population. Anyone with half a brain cell left knows you cannot take […]

[Continue reading...]

New Study: HPV Vaccine and Evidence of Herd Immunity or Type Replacement?

By 18 Comments

Sanevax square

By Norma Erickson, President Medical professionals rely on studies published in medical journals to keep abreast of new developments in their field. What happens when published studies raise more questions than answers? Where does that leave trusting medical consumers? On July 12, 2012, Australia became the first country in the world to formally offer taxpayer […]

[Continue reading...]

Human papillomavirus genotype distribution among French women with and without cervical abnormalities.

By Leave a Comment

Int J Gynaecol Obstet. 2011 Aug;114(2):116-9. Epub 2011 Jun 12. Casalegno JS, Benchaib M, Le Bail Carval K, Piaton E, Mathevet P, Mekki Y. Source: Laboratory of Virology, Femme-Mère-Enfant Hospital, Bron, France.   Abstract OBJECTIVE: To assess human papillomavirus (HPV) prevalence and distribution among French women with normal and pathologic cytology findings. METHODS: A genomic DNA microarray assay enabling the detection […]

[Continue reading...]

News

Videos

Contact